These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. Grebe A; Hoss F; Latz E Circ Res; 2018 Jun; 122(12):1722-1740. PubMed ID: 29880500 [TBL] [Abstract][Full Text] [Related]
5. Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases. Ji E; Lee S Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071276 [TBL] [Abstract][Full Text] [Related]
7. RP5-833A20.1/miR-382-5p/NFIA-dependent signal transduction pathway contributes to the regulation of cholesterol homeostasis and inflammatory reaction. Hu YW; Zhao JY; Li SF; Huang JL; Qiu YR; Ma X; Wu SG; Chen ZP; Hu YR; Yang JY; Wang YC; Gao JJ; Sha YH; Zheng L; Wang Q Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):87-101. PubMed ID: 25265644 [TBL] [Abstract][Full Text] [Related]
8. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Ridker PM Cardiovasc Res; 2021 Sep; 117(11):e138-e140. PubMed ID: 34352102 [No Abstract] [Full Text] [Related]
9. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Abbate A; Toldo S; Marchetti C; Kron J; Van Tassell BW; Dinarello CA Circ Res; 2020 Apr; 126(9):1260-1280. PubMed ID: 32324502 [TBL] [Abstract][Full Text] [Related]
10. Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches. Park KH; Park WJ J Korean Med Sci; 2015 Sep; 30(9):1213-25. PubMed ID: 26339159 [TBL] [Abstract][Full Text] [Related]
13. A perspective on targeting inflammation and cytokine actions in atherosclerosis. Chan YH; Ramji DP Future Med Chem; 2020 Apr; 12(7):613-626. PubMed ID: 32175772 [TBL] [Abstract][Full Text] [Related]
14. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy. Dhorepatil A; Ball S; Ghosh RK; Kondapaneni M; Lavie CJ Am J Med; 2019 Mar; 132(3):312-324. PubMed ID: 30832770 [TBL] [Abstract][Full Text] [Related]
15. Inflammasomes as Potential Therapeutic Targets in Atherosclerotic Cardiovascular Disease. Wang P; Ma J; Zhang R Endocr Metab Immune Disord Drug Targets; 2022; 22(14):1378-1389. PubMed ID: 35392792 [TBL] [Abstract][Full Text] [Related]
16. IgE Contributes to Atherosclerosis and Obesity by Affecting Macrophage Polarization, Macrophage Protein Network, and Foam Cell Formation. Zhang X; Li J; Luo S; Wang M; Huang Q; Deng Z; de Febbo C; Daoui A; Liew PX; Sukhova GK; Metso J; Jauhiainen M; Shi GP; Guo J Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):597-610. PubMed ID: 31996021 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. Jones SA; Scheller J; Rose-John S J Clin Invest; 2011 Sep; 121(9):3375-83. PubMed ID: 21881215 [TBL] [Abstract][Full Text] [Related]
18. Chlamydia pneumoniae Hijacks a Host Autoregulatory IL-1β Loop to Drive Foam Cell Formation and Accelerate Atherosclerosis. Tumurkhuu G; Dagvadorj J; Porritt RA; Crother TR; Shimada K; Tarling EJ; Erbay E; Arditi M; Chen S Cell Metab; 2018 Sep; 28(3):432-448.e4. PubMed ID: 29937375 [TBL] [Abstract][Full Text] [Related]
19. Mutual Interplay of Host Immune System and Gut Microbiota in the Immunopathology of Atherosclerosis. Yeh CF; Chen YH; Liu SF; Kao HL; Wu MS; Yang KC; Wu WK Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33227973 [TBL] [Abstract][Full Text] [Related]